Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013
This article was originally published in The Pink Sheet Daily
Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.
You may also be interested in...
San Francisco-based VC also is an investor in a $200 million Series DD funding for type 2 diabetes-focused Intarcia Therapeutics. Foresite will use the same investment strategy for its second fund, seeking late-stage investments in proven technologies with strong management and promising market positions.
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
Belgium's Bone Therapeutics raises $10.4 million in a Series D financing to fund a Phase III study of its lead product, an osteoblast cell therapy for osteonecrosis of the hip and non-union bone fractures.